Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

In-Situ Ligand-Induced Chirality Transfer in Emissive CdSe Nanoplatelets.

Created on 17 Jun 2026

Authors

William Girten, Farwa Awan, Nikita S Dutta, Marissa Martinez, Jacob L Shelton, Margherita Taddei, Todd D Krauss, Joseph M Luther, Md Azimul Haque, Matthew C Beard

Published in

The journal of physical chemistry letters. Jun 17, 2026. Epub Jun 17, 2026.

Abstract

Terminating semiconductor nanocrystals with chiral organic ligands can induce chiroptical properties that combine the chiral character of the ligands with the strong and tunable optical properties of the nanocrystal. However, the synthesis of such chiral-modified nanocrystals is currently limited by solvent incompatibility between polar chiral ligands and nonpolar traditional ligands, as well as by ligand dissolution behavior that ultimately compromises nanocrystal quality and the degree to which chiroptical properties can be manipulated. In this work, we demonstrate a single-step synthesis of chiral cadmium selenide (CdSe) nanoplatelets (NPLs) that eliminates the need for postsynthetic ligand exchange in aqueous solvents, resulting in highly emissive chiral CdSe NPLs. By directly incorporating chiral aminodecanoic acid ligands during synthesis, we achieve in situ ligand binding and chirality transfer to CdSe NPLs. This approach produces CdSe NPLs with high photoluminescence quantum efficiencies of 50% and circular dichroism dissymmetry factors (gCD) on the order of 10-4.

PMID:
42307900
Bibliographic data and abstract were imported from PubMed on 17 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement